VCANBIO - Public Comps and Valuation Multiples

VCANBIO Overview

About VCANBIO

Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.

Founded

1992

HQ

Employees

1.5K+

Website

vcanbio.com

Sectors

Regenerative Medicine
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$1.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

VCANBIO Financials

VCANBIO has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, VCANBIO achieved revenue of $218M and an EBITDA of $38.2M.

VCANBIO expects next 12-month revenue of XXX and NTM EBITDA of XXX

See VCANBIO valuation multiples based on analyst estimates

VCANBIO P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$218M	$218M	XXX	XXX	XXX
Gross Profit	$144M	$151M	XXX	XXX	XXX
Gross Margin	66%	69%	XXX	XXX	XXX
EBITDA	$38.0M	$38.2M	XXX	XXX	XXX
EBITDA Margin	17%	18%	XXX	XXX	XXX
Net Profit	$15.5M	$14.6M	XXX	XXX	XXX
Net Margin	7%	7%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

VCANBIO Stock Performance

As of April 25, 2025, VCANBIO's stock price is CNY 22 (or $3).

VCANBIO has current market cap of CNY 10.1B (or $1.4B), and EV of CNY 8.6B (or $1.2B).

See VCANBIO trading valuation data

VCANBIO Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.2B	$1.4B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

VCANBIO Valuation Multiples

As of April 25, 2025, VCANBIO has market cap of $1.4B and EV of $1.2B.

VCANBIO's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate VCANBIO's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for VCANBIO and 10K+ public comps

VCANBIO Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$1.2B	XXX	XXX	XXX
EV/Revenue	5.4x	XXX	XXX	XXX
EV/EBITDA	31.0x	XXX	XXX	XXX
P/E	100.4x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	39.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get VCANBIO Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

VCANBIO Valuation Multiples

VCANBIO's NTM/LTM revenue growth is n/a

VCANBIO's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, VCANBIO's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate VCANBIO's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for VCANBIO and other 10K+ public comps

VCANBIO Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	0%	XXX	XXX	XXX	XXX
EBITDA Margin	18%	XXX	XXX	XXX	XXX
EBITDA Growth	1%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	$0.1M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	22%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	17%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	11%	XXX	XXX	XXX	XXX
Opex to Revenue	56%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Streaming Platforms

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Explore Valuation Multiples by Industry